INOVIO to Participate in Upcoming Scientific Conferences

Rhea-AI Summary

INOVIO (NASDAQ:INO) will present posters at two upcoming scientific conferences in May 2026: the American Society of Gene and Cell Therapy (Boston) and the American Society of Clinical Oncology (Chicago). Presentations cover hemophilia A gene transfer and INO-3107 DNA immunotherapy for recurrent respiratory papillomatosis. Available abstracts will be posted on the company website after each presentation.

AI-generated analysis. Not financial advice.

News Market Reaction – INO

+6.57% 5.3x vol

44 alerts

+6.57% News Effect

+23.1% Peak in 9 hr 34 min

+$9M Valuation Impact

$145.64M Market Cap

5.3x Rel. Volume

On the day this news was published, INO gained 6.57%, reflecting a notable positive market reaction. Argus tracked a peak move of +23.1% during that session. Our momentum scanner triggered 44 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $145.64M at that time. Trading volume was exceptionally heavy at 5.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:

American Society of Gene and Cell Therapy Annual Meeting (Boston)
Poster Presentation: Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells
Date: Tuesday, May 12
Time: 5 - 6:30 PM ET

American Society of Clinical Oncology Annual Meeting (Chicago)
Poster Presentation: B cell responses in Recurrent Respiratory Papillomatosis patients treated with DNA immunotherapy INO-3107
Date: Saturday, May 30
Time: 1:30 - 4:30 PM CDT

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302766450.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO (INO) present at the ASGCT 2026 meeting in Boston?

INOVIO will present a poster at ASGCT on May 12, 2026, 5:00–6:30 PM ET. According to INOVIO, the poster covers bleeding-phenotype correction in hemophilia A mice after in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells.

What is INOVIO presenting at ASCO 2026 in Chicago and when is the poster session?

INOVIO will present a poster on INO-3107 B cell responses in recurrent respiratory papillomatosis on May 30, 2026, 1:30–4:30 PM CDT. According to INOVIO, the session reports clinical immune-response data from treated patients.

Where can investors find the INOVIO (INO) abstracts from the May 2026 conference presentations?

Abstracts will be posted on INOVIO's investor website after each presentation. According to INOVIO, available abstracts will be shared on the company website following the May 12 and May 30 poster sessions.

Do the INOVIO (INO) May 2026 posters include clinical data relevant to investors?

One poster describes preclinical hemophilia A gene-transfer results and the other reports clinical immune responses for INO-3107. According to INOVIO, the ASCO poster presents B cell response data from treated patients, which investors may review once abstracts are posted.

How can investors attend or view INOVIO (INO) presentations at ASGCT and ASCO 2026?

Investors can attend the conference poster sessions in person or wait for posted abstracts on INOVIO's website. According to INOVIO, abstracts will be made available online after each May presentation for remote review.